Align Has More To Smile About After Elliott’s Stake

Align may have found a new reason to smile after Elliott Investment Management took a significant stake in the maker of Invisalign. Elliott plans to engage with the company on strategies to boost the stock price, turning the disclosure into something more meaningful than a routine filing. It is also now one of Align’s largest investors, which gives the development more weight than the average market rumor and suggests this is a shareholder with both conviction and the kind of scale that can usually clean things up.

The opportunity becomes easier to see once you separate the stock chart from the business underneath it. Align Technology has seen its shares fall more than 75% from their 2021 peak as demand for dental products slowed. That does not erase the brand, the installed base, or the company’s position in clear aligners. It does, however, create the kind of opening that can catch the eye of a shareholder looking for a strong franchise with a weaker stock chart than its business might justify. That is what gives Elliott’s move some real bite. This is not a forgotten business trying to explain why it exists, but an established one trying to convince the market it deserves a better valuation.

What makes the situation more interesting is that the business itself is not showing up empty-handed. Align finished 2025 with record total revenue of $4.0 billion, including $3.2 billion in Clear Aligner revenue and $789.6 million from Systems and Services, while fiscal 2025 Clear Aligner volumes reached a record 2.6 million cases. For 2026, the company said it expects worldwide revenue growth of 3% to 4% and mid-single-digit growth in Clear Aligner volume. Those are not the numbers of a company walking into the room with a paper cup and an apology. They suggest Align still has enough scale, momentum, and commercial relevance to make a large shareholder think the stock may be telling a gloomier story than the business itself.

Analysts expect sector-level demand to stabilize in 2026, even if they remain cautious about calling a full recovery, and now Align has a prominent investor leaning on the same door at the same time. It doesn't guarantee a turnaround, but it does give the stock a more interesting mix of ingredients than it has had in some time. A recognizable brand, a still-relevant business, and an activist with a reason to care can make even a long-slumping stock start to look like it may be ready for some corrective work of its own.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726